BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 [Yahoo! Finance]
BioAtla, Inc. (BCAB)
Company Research
Source: Yahoo! Finance
company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025. The presentation, titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC” , will be delivered by Dr. Mihaela Druta of Moffitt Cancer Center on Friday, November 7, 2025 . The abstract (#523) will be featured in the poster session, with presentation time to be announced. A copy of the presentation materials can be accessed on the “Publication” section of the Company's website at www.bioatla.co
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla Enters into Agreements for up to $22.5 Million Flexible FinancingGlobeNewswire
- BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]Yahoo! Finance
- BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]Seeking Alpha
- BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasGlobeNewswire
BCAB
Earnings
- 11/13/25 - Beat
BCAB
Sec Filings
- 12/5/25 - Form DEF
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- BCAB's page on the SEC website